These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27470635)

  • 1. [Research advances in the role of CX3CL1 and its receptor in liver diseases].
    Zhang P; He SS; Tong QX
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):313-6. PubMed ID: 27470635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Shen J; Huang CK; Yu H; Shen B; Zhang Y; Liang Y; Li Z; Feng X; Zhao J; Duan L; Cai X
    J Cell Mol Med; 2017 May; 21(5):986-992. PubMed ID: 28224705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.
    Ma WL; Lai HC; Yeh S; Cai X; Chang C
    Endocr Relat Cancer; 2014 Jun; 21(3):R165-82. PubMed ID: 24424503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transducer and activator of transcription 4 in liver diseases.
    Wang Y; Qu A; Wang H
    Int J Biol Sci; 2015; 11(4):448-55. PubMed ID: 25798064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokines in liver inflammation and fibrosis.
    Wasmuth HE; Tacke F; Trautwein C
    Semin Liver Dis; 2010 Aug; 30(3):215-25. PubMed ID: 20665374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human alpha 1-microglobulin in various hepatic disorders.
    Itoh Y; Enomoto H; Takagi K; Kawai T; Yamanaka T
    Digestion; 1983; 27(2):75-80. PubMed ID: 6195036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased proportion of proapolipoprotein A-I in HDL from patients with liver cirrhosis and hepatitis.
    Matsuura T; Koga S; Ibayashi H
    Gastroenterol Jpn; 1988 Aug; 23(4):394-400. PubMed ID: 2846400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.
    Pazirandeh S; Khettry U; Gordon FD; Resnick RH; Murray JE; Sheth SG
    Dig Dis Sci; 2007 Jan; 52(1):220-7. PubMed ID: 17160481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of MCP/CCR2 in patients of hepatocellular carcinoma and liver cirrhosis].
    Fang N; Fan X; Zhang XS
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):553-4. PubMed ID: 19912695
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma.
    Sun L; Dai JJ; Hu WF; Wang J
    Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27420991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells.
    Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY
    Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Hepatitis C Virus in the dynamic protein interaction networks of hepatocellular cirrhosis and carcinoma.
    Huang T; Liu L; Liu Q; Ding G; Tan Y; Tu Z; Li Y; Dai H; Xie L
    Int J Comput Biol Drug Des; 2011; 4(1):5-18. PubMed ID: 21330691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum trypsin inhibitory capacity and alpha 1-antitrypsin levels in liver cirrhosis and hepatoma.
    Theodoropoulos G; Archimandritis A; Tsomi A; Chloros G; Rigatos G; Angelopoulos B
    Acta Hepatogastroenterol (Stuttg); 1979 Jun; 26(3):195-7. PubMed ID: 225915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease.
    Jaskiewicz K; Chasen MR; Robson SC
    Anticancer Res; 1993; 13(6A):2229-37. PubMed ID: 8297138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood clearance rate as an adjunct to the 198 Au hepatoscan.
    Bahk YW
    Br J Radiol; 1972 Jan; 45(529):24-30. PubMed ID: 4332734
    [No Abstract]   [Full Text] [Related]  

  • 16. Protectin D1 reduces concanavalin A-induced liver injury by inhibiting NF-κB-mediated CX3CL1/CX3CR1 axis and NLR family, pyrin domain containing 3 inflammasome activation.
    Ren J; Meng S; Yan B; Yu J; Liu J
    Mol Med Rep; 2016 Apr; 13(4):3627-38. PubMed ID: 26955849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
    Kang HJ; Chung DH; Sung CO; Yoo SH; Yu E; Kim N; Lee SH; Song JY; Kim CJ; Choi J
    Oncotarget; 2017 Apr; 8(16):27263-27276. PubMed ID: 28460481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deranged metabolism of cyclic nucleotides in liver diseases.
    Matsushima T; Maekubo H; Yoshida T; Taneda H; Yoshida J; Miyazaki T; Okada F
    Horm Metab Res; 1985 Jun; 17(6):306-7. PubMed ID: 2991101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells.
    Li F; Wang Z; Liu Y; Li J
    Oncol Rep; 2010 Sep; 24(3):669-75. PubMed ID: 20664972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate changes in liver disease.
    Sherlock S
    Am J Clin Nutr; 1970 Apr; 23(4):462-6. PubMed ID: 4315010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.